Acamprosate, oral naltrexone linked to improved outcomes for alcohol use disorder

Healio (12/5, Burba) reports a study found “acamprosate and oral naltrexone were associated with significantly improved alcohol consumption outcomes compared with placebo and could be used alongside psychosocial interventions as first-line treatment for alcohol use disorder.” The researchers said, “In conjunction with psychosocial interventions, these findings support the use of oral naltrexone, 50 mg/d, and acamprosate as first-line pharmacotherapies for alcohol use disorder.” The findings were published in JAMA.

Related Links:

— “,” Kate Burba, Healio, December 5, 2023

Posted in In The News.